# Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin

> **NCT02212795** · PHASE1 · COMPLETED · sponsor: **Dong Wha Pharmaceutical Co. Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Zabofloxacin 183mg
- **DRUG:** Levofloxacin 250mg
- **DRUG:** Zabofloxacin 367mg

## Key facts

- **NCT ID:** NCT02212795
- **Lead sponsor:** Dong Wha Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2014-08
- **Final completion:** 2014-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2015-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02212795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02212795, "Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02212795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*